menu

Community-acquired Bacterial Pneumonia Treatment Market

Schedule Call

Community-acquired Bacterial Pneumonia Treatment Market

Community-acquired Bacterial Pneumonia Treatment Market by Treatment Type (Antibiotics, Antivirals), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Global Outlook & Forecast 2022-2030

GR - 805135 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: February 27, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Community-acquired Bacterial Pneumonia Treatment Market Scope

Report Attribute

Details

Market Size Value in 2021

US$ 1.50 billion

Revenue Forecast in 2030

US$ 2.67 billion

CAGR

6.6%

Base Year for Estimation

2021

Forecast Period

2022-2030

Historical Year

2020

Segments Covered

Treatment Type, Route of administration, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global community-acquired bacterial pneumonia treatment market was valued at US$ 1.50 billion in 2021 and is expected to register a revenue CAGR of 6.6% to reach US$ 2.67 billion by 2030.

Community-acquired Bacterial Pneumonia Treatment Market Fundamentals

Community-acquired bacterial pneumonia is a type of pneumonia that develops outside of hospitals or healthcare settings. It is a common condition that occurs when bacteria infect the lungs, causing inflammation and the accumulation of fluid in the air sacs of the lungs. The most common bacteria that cause community-acquired bacterial pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumonia. Symptoms of community-acquired bacterial pneumonia typically include coughing, fever, chest pain, shortness of breath, fatigue, and chills. The severity of symptoms can vary depending on the individual and the type of bacteria causing the infection.

The diagnosis of community-acquired bacterial pneumonia involves a physical examination, medical history review, and tests, such as a chest X-ray, blood tests, and sputum culture. The treatment usually involves a course of antibiotics to target the specific bacteria causing the infection. In severe cases, hospitalization may be necessary for intravenous antibiotics and supportive care. Prevention of community-acquired bacterial pneumonia includes practicing good hygiene, such as washing hands frequently, avoiding close contact with sick individuals, and getting vaccinated against the flu and pneumonia.

Community-acquired bacterial pneumonia is usually treated with antibiotics to target the specific bacteria causing the infection. The choice of antibiotics depends on several factors, including the severity of the infection, the patient’s age and health status, and the prevalence of antibiotic resistance in the community.

[6575755]

Community-acquired Bacterial Pneumonia Treatment Market Dynamics

The global prevalence of community-acquired bacterial pneumonia is on the rise due to various factors, such as the aging population, smoking, and environmental pollution. For instance, according to November 2022 article by the Centers For Diseases Control And Prevention (CDC), there are about 40 million smokers in the United States; and a half million Americans die prematurely due to smoking or exposure to secondhand smoke. The rise of antibiotic-resistant bacteria has resulted in an urgent need for the development of new antibiotics that are effective against these pathogens. Thus, there has been a surge in research and development activities in the field of antibacterial drugs. These factors are expected to drive the revenue growth of the global community-acquired bacterial pneumonia treatment market. Additionally, the surge in the number of drug approvals, product launches, and pipeline drugs is also resulting in the rapid development of the global community-acquired bacterial pneumonia treatment market. The growing awareness about the severity of community-acquired bacterial pneumonia and its complications is expected to increase the demand for its treatment. 

The increasing awareness among healthcare professionals about the proper diagnosis and treatment of community-acquired bacterial pneumonia is expected to boost the revenue growth of the global market. Moreover, various governments across the world are investing in research and development activities for the development of new antibiotics and are also taking initiatives to promote the proper diagnosis and treatment of community-acquired bacterial pneumonia. These initiatives and funding are projected to drive the revenue growth of the global community-acquired bacterial pneumonia treatment market.

However, the high cost associated with research and development, the shortage of skilled professionals, and the lack of advanced healthcare infrastructure in developing economies are key restraints for the overall market revenue growth.

Community-acquired Bacterial Pneumonia Treatment Market Ecosystem

The global community-acquired bacterial pneumonia treatment market is analyzed from four perspectives: treatment type, route of administration, distribution channel, and region.

Community-acquired Bacterial Pneumonia Treatment Market by Treatment Type

[856756] 

Based on the treatment type, the global community-acquired bacterial pneumonia treatment market is segmented into antibiotics, antivirals, and others.

The antibiotics segment dominated the market with the principal revenue share in 2021, as antibiotics are used as first-line agents in treating community-acquired bacterial pneumonia. The increasing prevalence of drug-resistant strains of bacteria has led to the development of new antibiotics and combination therapies. Additionally, there are several classes of antibiotics available for the treatment of community-acquired bacterial pneumonia, including macrolides, fluoroquinolones, penicillin, and cephalosporins. The availability of a wide range of antibiotics has increased the options available to healthcare providers for the treatment of community-acquired bacterial pneumonia. Moreover, the significant progress in the development of new antibiotics, including novel mechanisms of action and improved pharmacokinetic properties, has improved the efficacy and safety of antibiotics and driven the revenue growth of the antibiotics segment. 

Community-acquired Bacterial Pneumonia Treatment Market by Route of Administration

Based on the route of administration, the global community-acquired bacterial pneumonia treatment market is segmented into oral and intravenous. 

The oral segment dominated the market with the largest revenue share in 2021, attributed to high patient preference for oral medications, the availability of effective oral antibiotics, and a lower risk of sequelae. Many patients prefer oral medications over other routes of administration, such as injections or intravenous infusions. Oral medications are generally more convenient and less invasive, which can lead to better patient compliance. Additionally, there are several effective oral antibiotics available for the treatment of community-acquired bacterial pneumonia, such as macrolides, penicillin, and fluoroquinolones. These antibiotics can be used to treat mild to moderate cases of community-acquired bacterial pneumonia. Many patients with mild to moderate community-acquired bacterial pneumonia can be treated on an outpatient basis with oral antibiotics. This can reduce the burden on hospitals and healthcare systems. These factors contribute to the revenue growth of the oral route segment.

Community-acquired Bacterial Pneumonia Treatment Market by Distribution Channel 

Based on the distribution channel, the global community-acquired bacterial pneumonia treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

The hospital pharmacy segment dominated the market with the largest revenue share in 2021, owing to the large footfall of patients. Hospital pharmacies have access to specialized healthcare professionals, such as infectious disease specialists, who can provide expert advice on the appropriate usage of antibiotics for the treatment of community-acquired bacterial pneumonia. Many patients with severe cases of this type of pneumonia require hospitalization and inpatient treatment. Hospital pharmacies are equipped to provide the necessary medications and supportive therapies for these patients. They often have centralized ordering and distribution systems, which can improve the efficiency and accuracy of medication administration for community-acquired bacterial pneumonia patients. These overarching variables contribute to the hospital pharmacy segment revenue growth.

Community-acquired Bacterial Pneumonia Treatment Market by Region

Geographically, the global community-acquired bacterial pneumonia treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominated the global market with the largest revenue share in 2021, attributed to increasing research and development activities, rising healthcare expenditure, and the presence of major key players. Additionally, companies across the region are continuously working on launching novel medications for the treatment of community-acquired bacterial pneumonia, which is also helping in the growth of the regional market.

Community-acquired Bacterial Pneumonia Treatment Market Competitive Landscape

The prominent players operating in the global community-acquired bacterial pneumonia treatment market are:

Community-acquired Bacterial Pneumonia Treatment Market Strategic Developments

  • In January 2023, Paratek Pharmaceuticals, Inc., a biopharmaceutical firm specializing in the research and marketing of innovative life-saving medicines for fatal conditions, announced that its intravenous (IV) formulation of NUZYRA (omadacycline) has been added to China’s National Reimbursement Drug List (NRDL) for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in China. In the United States, NUZYRA is a once-daily oral and intravenous antibiotic approved for the treatment of people with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
  • In December 2022, Clarametyx Biosciences launched the Phase Ia antibody study for bacterial pneumonia. The study was expected to look at the safety of up to four doses of the antibody in healthy people. The company was expected to begin the placebo-controlled, double-blind, randomized Phase Ib segment when the Phase Ia section of the trial was completed. The trial’s commencement was supported by many preclinical investigations in which CMTX-101 demonstrated anti-biofilm efficacy. CMTX-101, a novel antibody, has been developed to treat severe bacterial infections. It rapidly destroys the universal underlying structure of bacterial biofilms, weakening extracellular bacterial defenses and allowing for effective antibiotic and immunological intervention.
  • In November 2022, Eagle Pharmaceuticals, Inc. announced that the U.S. FDA had accepted its investigational new drug (IND) application for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjuvant treatment of severe community-acquired bacterial pneumonia. The Phase 2 research was expected to enroll about 276 patients with severe community-acquired pneumonia at around 120 locations worldwide as early as the beginning of 2023.

Frequently Asked Questions About This Report

The global community-acquired bacterial pneumonia treatment market is expected to reach US$ 2.67 billion by 2030.

The community-acquired bacterial pneumonia treatment market is expected to register growth at a revenue CAGR of 6.6% during the forecast period from 2022 to 2030.

The development of new antibiotics leading to rising drug approvals and launches and the increasing prevalence of community-acquired bacterial pneumonia are driving the growth of the global market.

The costs associated with research and development, the shortage of skilled professionals, and the lack of healthcare infrastructure in developing economies are restricting the global market revenue growth to its full potential.

Nabriva Therapeutics plc, Cumberland Pharmaceuticals Inc., Paratek Pharmaceuticals, Inc., Merck Sharp & Dohme Inc., and Cubist Pharmaceuticals LLC are among the top market players.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Antibiotics
    2. Antivirals
    3. Others
  6. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral
    2. Intravenous
  7. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL 
    1. Hospitals Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  8. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Community Acquired Bacterial Pneumonia Treatment Market
      1. North America Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type
      2. North America Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
      3. North America Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
      4. North America Community Acquired Bacterial Pneumonia Treatment Market, by Country
        1. U.S.
          1. U.S. Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type
          2. U.S. Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration 
          3. U.S. Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Canada Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Canada Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
    2. Europe Community Acquired Bacterial Pneumonia Treatment Market
      1. Europe Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
      2. Europe Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
      3. Europe Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
      4. Europe Community Acquired Bacterial Pneumonia Treatment Market, by Country/Region
        1. Germany
          1. Germany Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Germany Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Germany Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel 
        2. U.K.
          1. U.K. Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. U.K. Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. U.K. Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        3. France
          1. France Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. France Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. France Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Spain Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Spain Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        5. Italy
          1. Italy Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Italy Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Italy Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        6. Rest of Europe 
          1. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
    3. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market
      1. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
      2. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
      3. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
      4. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Country/Region
        1. China
          1. China Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. China Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. China Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        2. Japan
          1. Japan Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Japan Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Japan Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        3. India
          1. India Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. India Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. India Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        4. South Korea
          1. South Korea Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. South Korea Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. South Korea Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type
          2. Australia Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration 
          3. Australia Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
    4. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market
      1. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
      2. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
      3. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
      4. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, by Region
        1. Latin America
          1. Latin America Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Latin America Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Latin America Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
        2. Middle East & Africa
          1. Middle East & Africa Community Acquired Bacterial Pneumonia Treatment Market, by Treatment Type 
          2. Middle East & Africa Community Acquired Bacterial Pneumonia Treatment Market, by Route of Administration
          3. Middle East & Africa Community Acquired Bacterial Pneumonia Treatment Market, by Distribution Channel
  9. COMPANY PROFILES         
    1. Nabriva Therapeutics plc
      1. Business Snapshot 
      2. Class Offered
      3. Financial Details
      4. Strategic Development
    2. Cumberland Pharmaceuticals Inc.
    3. Paratek Pharmaceuticals, Inc. 
    4. Eagle Pharmaceutical Inc.
    5. Pfizer Inc. 
    6. Eli Lilly & Company
    7. GSK plc
    8. Forest Pharmaceuticals
    9. Sanofi S.A.
    10. Teva Pharmaceuticals Industries Limited
    11. Merck Sharp & Dohme Inc.
    12. Cubist Pharmaceuticals LLC
    13. Shionogi Inc.

*Insights on financial performance are subject to the availability of information in the public domain

 

List of Tables

 

  1. Global Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  2. Global Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  3. Global Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  4. Global Community Acquired Bacterial Pneumonia Treatment Market, by Region, 2020-2030 (US$ Million) 
  5. North America Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  6. North America Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million) 
  7. North America Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)
  8. North America Community Acquired Bacterial Pneumonia Treatment Market, By Country, 2020-2030 (US$ Million) 
  9. U.S. Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  10. U.S. Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  11. U.S. Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  12. Canada Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  13. Canada Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  14. Canada Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  15. Europe Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  16. Europe Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  17. Europe Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  18. Europe Community Acquired Bacterial Pneumonia Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  19. Germany Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  20. Germany Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  21. Germany Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  22. U.K. Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  23. U.K. Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  24. U.K. Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  25. France Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  26. France Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  27. France Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  28. Italy Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  29. Italy Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  30. Italy Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  31. Spain Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  32. Spain Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million
  33. Spain Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  34. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  35. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million
  36. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  37. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  38. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  39. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  40. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  41. China Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  42. China Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  43. China Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  44. Japan Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  45. Japan Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  46. Japan Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  47. India Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  48. India Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million
  49. India Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  50. South Korea Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  51. South Korea Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  52. South Korea Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  53. Australia Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  54. Australia Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  55. Australia Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  56. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  57. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  58. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  59. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  60. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  61. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)
  62. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, By Region, 2020-2030 (US$ Million) 
  63. Latin America Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  64. Latin America Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million)
  65. Latin America Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  66. Middle East and Africa Community Acquired Bacterial Pneumonia Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  67. Middle East and Africa Community Acquired Bacterial Pneumonia Treatment Market, By Route of Administration, 2020-2030 (US$ Million) 
  68. Middle East and Africa Community Acquired Bacterial Pneumonia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 

 

List of Figures

 

  1. Community Acquired Bacterial Pneumonia Treatment Market Ecosystem  
  2. Snapshot of Global Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 
  3. Snapshot of Global Community Acquired Bacterial Pneumonia Treatment Market, By Region, 2020-2030 
  4. Global Community Acquired Bacterial Pneumonia Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Community Acquired Bacterial Pneumonia Treatment Market: Key Players & Competitive Positioning (2021) 
  6. Community Acquired Bacterial Pneumonia Treatment: Market Dynamics 
  7. Global Community Acquired Bacterial Pneumonia Treatment Market for Antibiotics, 2020-2030 (US$ Million) 
  8. Global Community Acquired Bacterial Pneumonia Treatment Market for Antivirals, 2020-2030 (US$ Million) 
  9. Global Community Acquired Bacterial Pneumonia Treatment Market for Others, 2020-2030 (US$ Million) 
  10. Global Community Acquired Bacterial Pneumonia Treatment Market for Oral, 2020-2030 (US$ Million) 
  11. Global Community Acquired Bacterial Pneumonia Treatment Market for Intravenous, 2020-2030 (US$ Million) 
  12. Global Community Acquired Bacterial Pneumonia Treatment Market for Hospital Pharmacy, 2020-2030 (US$ Million)
  13. Global Community Acquired Bacterial Pneumonia Treatment Market for Retail Pharmacy2020-2030 (US$ Million)
  14. Global Community Acquired Bacterial Pneumonia Treatment Market for Online Pharmacy, 2020-2030 (US$ Million)
  15. North America Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  16. U.S. Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  17. Canada Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  18. Europe Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  19. Germany Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  20. U.K. Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  21. France Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  22. Italy Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  23. Spain Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  24. Rest of Europe Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  25. Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  26. China Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  27. Japan Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  28. India Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  29. South Korea Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  30. Australia Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  31. Rest of Asia Pacific Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  32. Rest of the World Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  33. Latin America Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  34. Middle East & Africa Community Acquired Bacterial Pneumonia Treatment Market, 2020-2030 (US$ Million) 
  35. Nabriva Therapeutics plc Revenue from 2018-2021 (US$ Million)
  36. Cumberland Pharmaceuticals Inc. Revenue from 2018-2021 (US$ Million)
  37. Paratek Pharmaceuticals, Inc. Revenue from 2018-2021 (US$ Million)
  38. Eagle Pharmaceutical Inc. Revenue from 2018-2021 (US$ Million)
  39. Pfizer Inc. Revenue from 2018-2021 (US$ Million)
  40. Eli Lilly & Company Revenue from 2018-2021 (US$ Million)
  41. GSK plc Revenue from 2018-2021 (US$ Million)
  42. Forest Pharmaceuticals Revenue from 2018-2021 (US$ Million)
  43. Sanofi S.A. Revenue from 2018-2021 (US$ Million)
  44. Teva Pharmaceuticals Industries Limited Revenue from 2018-2021 (US$ Million)
  45. Merck Sharp & Dohme Inc. Revenue from 2018-2021 (US$ Million)
  46. Cubist Pharmaceuticals LLC Revenue from 2018-2021 (US$ Million)
  47. Shionogi Inc. Revenue from 2018-2021 (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Community-acquired Bacterial Pneumonia Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Community-acquired Bacterial Pneumonia Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports